据悉，塔戈利单抗注射液是一种人源化IgG1κ亚型单克隆抗体，可特异性结合细胞程序性死亡配体-1（PD-L1），阻断其与程序性死亡受体-1（PD-1）之间的相互作用，从而解除肿瘤细胞通过PD-1/PD-L1通路对T细胞的抑制作用，使免疫细胞重新发挥抗肿瘤细胞免疫作用。该品种的上市为鼻咽癌患者提供了新的治疗选择。SKB BIO-B (06990) rose over 4% in the morning session. As of the time of writing, it has increased by 4.53%, reaching 170.7 Hong Kong dollars, with a trading volume of 9.4408 million Hong Kong dollars.
Zhitong Finance APP reports that SKB BIO-B (06990) rose over 4% in early trading, and as of the time of writing, it has increased by 4.53%, priced at 170.7 Hong Kong dollars, with a transaction volume of 9.4408 million Hong Kong dollars.
In terms of news, SKB BIO released an announcement stating that its innovative humanized monoclonal antibody, Tagolisumab (formerly known as KL-A167) designed for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have previously failed second-line or higher chemotherapy, has been approved by the National Medical Products Administration for listing in China.
It is reported that Tagolisumab injection is a humanized IgG1κ subtype monoclonal antibody that specifically binds to programmed death ligand-1 (PD-L1), blocking its interaction with programmed death receptor-1 (PD-1), thereby relieving the inhibitory effect on T cells exerted by tumor cells through the PD-1/PD-L1 pathway, allowing immune cells to re-establish their anti-tumor immune functions. The launch of this product provides new treatment options for nasopharyngeal carcinoma patients.